Trinity biotech further strengthens focus on continuous glucose monitoring – appoints barclays to advise on ongoing strategic realignment process

Dublin and portland, ore., march 13, 2025 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“cgm”) technology with the appointment of barclays capital inc. (“barclays”) as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the company's increased focus on its cgm technology as part of its broader transformation plan.
TRIB Ratings Summary
TRIB Quant Ranking